Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis

Andrea Gilioli, Andrea Messerotti, Paola Bresciani, Angela Cuoghi, Valeria Pioli, Corrado Colasante, Francesca Bettelli, Davide Giusti, Fabio Forghieri, Leonardo Potenza, Francesca Donatelli, Rachele Giubbolini, Laura Galassi, Roberto Marasca, Federico Banchelli, Roberto D'Amico, Monica Pecorari, William Gennari, Tommaso Trenti, Patrizia ComoliMario Luppi, Franco Narni

Research output: Contribution to journalArticlepeer-review

Abstract

Human cytomegalovirus (CMV) represents the most common viral infection after hematopoietic stem cell transplant (HSCT), mainly occurring as reactivation from latency in seropositive patients, with a different prevalence based on the extent and timing of seroconversion in a specific population. Here, we retrospectively analyzed a cohort of patients who underwent HSCT at our Institution between 2013 and 2018, all of whom were prophylactically treated with CMV-IG (Megalotect Biotest®), to define the incidence and clinical outcomes of CMV reactivation and clinically significant infection. CMV infection occurred in 69% of our patient series, mainly resulting from reactivation, and CMV clinically significant infection (CS-CMVi) occurred in 48% of prophylactically treated patients. CMV infection and CS-CMVi impacted neither on relapse incidence nor on overall survival nor on relapse-free survival. Moreover, a very low incidence of CMV end-organ disease was documented. CMV-IG used alone as prophylactic therapy after HSCT does not effectively prevent CMV reactivation.

Original languageEnglish
JournalJournal of Medical Virology
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • CMV
  • CMV prophylaxis
  • CMV-specific immunoglobulins
  • hematopoietic stem cell transplantation

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis'. Together they form a unique fingerprint.

Cite this